MRG-004A is under clinical development by Shanghai Miracogen and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MRG-004A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MRG-004A is under development for the treatment of solid tumors including triple-negative breast cancer, pancreatic cancer and ovarian cancer. The drug candidate is an antibody-drug conjugate which is developed by based on ADC technology. It is administered through intravenous route and acts by targeting tissue factor (TF).
Shanghai Miracogen overview
Shanghai Miracogen., biotechnology company that offers development, clinical research and industrialization of new cancer targeted therapy drugs-the world’s cutting-edge technology Antibody Drug Conjugate (ADC) and innovative antibody anti-tumor drugs
For a complete picture of MRG-004A’s drug-specific PTSR and LoA scores, buy the report here.